Kevin S Hughes

List of Publications by Year
in descending order

219	9,784	53939 47	46524 93
papers	citations	h-index	g-index

228	228	228	9012
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nipple-Sparing Mastectomy versus Skin-Sparing Mastectomy: Does Saving the Nipple Impact Short- and Long-Term Patient Satisfaction?. Annals of Surgical Oncology, 2022, 29, 1033-1040.	0.7	5
2	Penetrance of male breast cancer susceptibility genes: a systematic review. Breast Cancer Research and Treatment, 2022, 191, 31-38.	1.1	10
3	Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies. Surgical Oncology Clinics of North America, 2022, 31, 109-126.	0.6	9
4	Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model. Journal of Clinical Oncology, 2022, 40, 1732-1740.	0.8	71
5	Optimizing risk-based breast cancer screening policies with reinforcement learning. Nature Medicine, 2022, 28, 136-143.	15.2	34
6	Magnetic Seeds: An Alternative to Wire Localization for Nonpalpable Breast Lesions. Clinical Breast Cancer, 2022, 22, e700-e707.	1.1	12
7	Validation of Breast Cancer Risk Models by Race/Ethnicity, Family History and Molecular Subtypes. Cancers, 2022, 14, 45.	1.7	11
8	Reply to M. Eriksson et al and Z. Jin et al. Journal of Clinical Oncology, 2022, , JCO2200292.	0.8	0
9	A Woman Needs to Know She Is a BRCA Carrier Before She Develops Breast Cancer. Annals of Surgical Oncology, 2022, 29, 4667-4669.	0.7	1
10	Utilizing Natural Language Processing (NLP) to identify breast cancer associated-lung metastases from pathology reports to delineate characteristics and challenges of this common site of breast cancer recurrence.. Journal of Clinical Oncology, 2022, 40, e13592-e13592.	0.8	0
11	Predominance of BRCA2 mutation and estrogen receptor-positive breast cancer among BRCA1/2 mutation carriers.. Journal of Clinical Oncology, 2022, 40, 551-551.	0.8	0
12	Mainstreamed genetic testing of patients with breast cancer: Experience from a single surgeonâ€™s practice in a large U.S. academic center.. Journal of Clinical Oncology, 2022, 40, 10577-10577.	0.8	0
13	Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation. Cancers, 2022, 14, 3266.	1.7	3
14	The Association Between Cardiac Mortality and Adjuvant Radiation Therapy Among Older Patients With Stage I Estrogen Positive Breast Cancer: A Surveillance, Epidemiology, and End Results (SEER)â€“Based Study on Cardiac Mortality and Radiation Therapy. Advances in Radiation Oncology, 2021, 6, 100633.	0.6	2
15	Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery. Breast Cancer Research and Treatment, 2021, 187, 145-153.	1.1	14
16	Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum. Annals of Surgical Oncology, 2021, 28, 6590-6600.	0.7	5
17	Familial pancreatic cancer: who should be considered for genetic testing?. Irish Journal of Medical Science, 2021, , 1.	0.8	3
18	Disease spectrum of gastric cancer susceptibility genes. Medical Oncology, 2021, 38, 46.	1.2	8

#	Article	IF	Citations
19	ASO Author Reflections: Developing a Clinician-Friendly Resource to Promote Awareness of Non-Medullary Thyroid Cancer Susceptibility Genes and Their Associated Diseases. Annals of Surgical Oncology, 2021, 28, 6601-6602.	0.7	1
20	Artificial Intelligenceâ€“Aided Precision Medicine for COVID-19: Strategic Areas of Research and Development. Journal of Medical Internet Research, 2021, 23, e22453.	2.1	21
21	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. European Journal of Cancer, 2021, 146, 30-47.	1.3	81
22	Management and outcomes of men diagnosed with primary breast cancer. Breast Cancer Research and Treatment, 2021, 188, 561-569.	1.1	7
23	Disease Spectrum of Breast Cancer Susceptibility Genes. Frontiers in Oncology, 2021, 11, 663419.	1.3	6
24	Search Behavior Regarding Cancer Susceptibility Genes Using a Clinical Decision Support Tool for Gene-Specific Penetrance: Content Analysis. JMIR Cancer, 2021, 7, e28527.	0.9	4
25	How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?. Annals of Surgical Oncology, 2021, 28, 5657-5662.	0.7	15
26	Relationship of established risk factors with breast cancer subtypes. Cancer Medicine, 2021, 10, 6456-6467.	1.3	45
27	ASO Visual Abstract: How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?. Annals of Surgical Oncology, 2021, 28, 594-595.	0.7	1
28	Second invasive breast cancers in patients treated with breast-conserving therapy. European Journal of Surgical Oncology, 2021, 47, 2492-2498.	0.5	5
29	Toward robust mammography-based models for breast cancer risk. Science Translational Medicine, 2021, 13, .	5.8	100
30	ASO Visual Abstract: Nipple-SparingÂMastectomyÂVersusÂSkin-SparingÂMastectomyâ€”DoesÂSaving theÂNippleÂHave an ImpactÂon Short- andÂLong-TermÂPatientÂSatisfaction?. Annals of Surgical Oncology, 2021, , 1.	0.7	0
31	Performance of Breast Cancer Risk-Assessment Models in a Large Mammography Cohort. Journal of the National Cancer Institute, 2020, 112, 489-497.	3.0	59
32	Long-Term Outcomes of Multiple-Wire Localizations for More Extensive Breast Cancer: Multiple-Wire Excision Does Not Increase Recurrence, Unplanned Imaging, or Biopsies. Clinical Breast Cancer, 2020, 20, 215-219.	1.1	4
33	Natural language processing to facilitate breast cancer research and management. Breast Journal, 2020, 26, 92-99.	0.4	32
34	Exploiting Rules to Enhance Machine Learning in Extracting Information From Multi-Institutional Prostate Pathology Reports. JCO Clinical Cancer Informatics, 2020, 4, 865-874.	1.0	5
35	Novel Body Composition Predictors of Outcome in Patients With Angiosarcoma of the Breast: A Preliminary Study. Journal of Computer Assisted Tomography, 2020, 44, 605-609.	0.5	1
36	Breast imaging, breast surgery, and cancer genetics in the age of COVIDâ€19. Cancer, 2020, 126, 4466-4472.	2.0	44

#	Article	IF	Citations
37	Node-Positive Patients Treated with Neoadjuvant Chemotherapy Can Be Spared Axillary Lymph Node Dissection with Wireless Non-Radioactive Localizers. Annals of Surgical Oncology, 2020, 27, 4819-4827.	0.7	32
38	Legacy Genetic Testing Results for Cancer Susceptibility: How Common are Conflicting Classifications in a Large Variant Dataset from Multiple Practices?. Annals of Surgical Oncology, 2020, 27, 2212-2220.	0.7	1
39	Penetrance of Colorectal Cancer Among Mismatch Repair Gene Mutation Carriers: A Meta-Analysis. JNCI Cancer Spectrum, 2020, 4, pkaa027.	1.4	17
40	The role of Micro-CT in imaging breast cancer specimens. Breast Cancer Research and Treatment, 2020, 180, 343-357.	1.1	35
41	Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis. JNCI Cancer Spectrum, 2020, 4, pkaa029.	1.4	41
42	Comparing and assessing the reported penetrance of cancer susceptibility genes for breast cancer.. Journal of Clinical Oncology, 2020, 38, 1520-1520.	0.8	0
43	Chemoprevention acceptance and adherence in women with high-risk breast lesions. Breast Journal, 2019, 25, 190-195.	0.4	13
44	Enhanced Recovery Minimizes Opioid Use and Hospital Stay for Patients Undergoing Mastectomy with Reconstruction. Annals of Surgical Oncology, 2019, 26, 3464-3471.	0.7	11
45	Trends in Unilateral and Contralateral Prophylactic Mastectomy Use in Ductal Carcinoma In Situ of the Breast: Patterns and Predictors. Annals of Surgical Oncology, 2019, 26, 3863-3873.	0.7	13
46	Radiofrequency identification tag localization is comparable to wire localization for non-palpable breast lesions. Breast Cancer Research and Treatment, 2019, 177, 735-739.	1.1	41
47	Incidental breast carcinoma: incidence, management, and outcomes in 4804 bilateral reduction mammoplasties. Breast Cancer Research and Treatment, 2019, 177, 741-748.	1.1	11
48	Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. Annals of Surgical Oncology, 2019, 26, 3025-3031.	0.7	184
49	Reply to M.S. Copur et al, A. Taylor et al, and P.S. Rajagopal et al. Journal of Clinical Oncology, 2019, 37, 2178-2180.	0.8	4
50	ASO Author Reflections: The Pressing Need for Germline Genetic Testing. Annals of Surgical Oncology, 2019, 26, 612-613.	0.7	0
51	Using Machine Learning and Natural Language Processing to Review and Classify the Medical Literature on Cancer Susceptibility Genes. JCO Clinical Cancer Informatics, 2019, 3, 1-9.	1.0	37
52	Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?. Breast Cancer Research and Treatment, 2019, 175, 1-4.	1.1	8
53	Proliferative Lesions Found at Reduction Mammaplasty: Incidence and Implications in 995 Breast Reductions. Plastic and Reconstructive Surgery, 2019, 143, 271e-275e.	0.7	17
54	Performance of Screening Breast MRI across Women with Different Elevated Breast Cancer Risk Indications. Radiology, 2019, 292, 51-59.	3.6	49

#	Article	IF	Citations
55	Diagnostic Value of Fine-Needle Aspiration in Male Breast Lesions. Acta Cytologica, 2019, 63, 319-327.	0.7	9
56	Nipple Discharge After Nipple-Sparing Mastectomy With and Without Associated Pregnancy. Clinical Breast Cancer, 2019, 19, e534-e539.	1.1	6
57	Germline Genetic Testing: What the Breast Surgeon Needs to Know. Annals of Surgical Oncology, 2019, 26, 2184-2190.	0.7	19
58	Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?. Journal of Clinical Oncology, 2019, 37, 453-460.	0.8	254
59	Twenty-Five Year Trends in the Incidence of Ductal Carcinoma in Situ in US Women. Journal of the American College of Surgeons, 2019, 228, 932-939.	0.2	13
60	Do Neural Information Extraction Algorithms Generalize Across Institutions?. JCO Clinical Cancer Informatics, 2019, 3, 1-8.	1.0	8
61	Validation of a Semiautomated Natural Language Processingâ€“Based Procedure for Meta-Analysis of Cancer Susceptibility Gene Penetrance. JCO Clinical Cancer Informatics, 2019, 3, 1-9.	1.0	21
62	Guidelines Do Not Proscribe Surgeons Performing Genetic Testing. JAMA Surgery, 2019, 154, 269.	2.2	0
63	Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. Annals of Surgical Oncology, 2019, 26, 55-61.	0.7	36
64	Pathologic findings in reduction mammoplasty specimens: a surrogate for the population prevalence of breast cancer and high-risk lesions. Breast Cancer Research and Treatment, 2019, 173, 201-207.	1.1	24
65	Comprehensive germline multigene panel testing changes clinical care for patients with breast cancer: Untapped clinical utility and PARP inhibitor trial eligibility.. Journal of Clinical Oncology, 2019, 37, 1583-1583.	0.8	0
66	Incidental atypical hyperplasia/LCIS in mammoplasty specimens and subsequent risk of breast cancer.. Journal of Clinical Oncology, 2019, 37, 1561-1561.	0.8	0
67	A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancerâ€Related Germline Mutations. Journal of Genetic Counseling, 2018, 27, 1187-1199.	0.9	38
68	Machine Learning Methods to Extract Documentation of Breast Cancer Symptoms From Electronic Health Records. Journal of Pain and Symptom Management, 2018, 55, 1492-1499.	0.6	60
69	Pathologic Upgrade Rates of High-Risk Breast Lesions on Digital Two-Dimensional vs Tomosynthesis Mammography. Journal of the American College of Surgeons, 2018, 226, 858-867.	0.2	20
70	The impact of patient age on breast cancer risk prediction models. Breast Journal, 2018, 24, 592-598.	0.4	8
71	Genetic Risk Prediction in Breast Cancer. , 2018, , 217-232.		1
72	Reply to E. Ramos et al. Journal of Clinical Oncology, 2018, 36, 520-520.	0.8	0

#	Article	IF	Citations
73	Managing Patient with Mutations in PALB2, CHEK2, or ATM. Current Breast Cancer Reports, 2018, 10, 74-82.	0.5	0
74	Pathologic findings in reduction mammoplasty procedures identified by natural language processing of breast pathology reports: A surrogate for the population incidence of cancer and high risk lesions.. Journal of Clinical Oncology, 2018, 36, e13569-e13569.	0.8	2
75	Breast Cancer Risk Prediction in Women with Atypical Breast Lesions. , 2018, , 103-113.		1
76	Radiation-Induced Angiosarcoma after Breast-Cancer Treatment. New England Journal of Medicine, 2017, 376, 367-367.	13.9	18
77	Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. Breast Cancer Research and Treatment, 2017, 164, 263-284.	1.1	130
78	Reassessing risk models for atypical hyperplasia: age may not matter. Breast Cancer Research and Treatment, 2017, 165, 285-291.	1.1	14
79	Using machine learning to parse breast pathology reports. Breast Cancer Research and Treatment, 2017, 161, 203-211.	1.1	87
80	Genetic Testing: What Problem Are We Trying to Solve?. Journal of Clinical Oncology, 2017, 35, 3789-3791.	0.8	54
81	Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. Journal of Clinical Oncology, 2017, 35, 3153-3159.	0.8	20
82	Risk Assessment for Breast Cancer. , 2017, , 1-14.		0
83	Data Sharing to Support the Cancer Journey in the Digital Era. Journal of Oncology Practice, 2016, 12, 201-207.	2.5	4
84	Fine-Needle Aspiration Biopsy of Palpable Breast Masses: Patterns of Clinical Use and Patient Experience. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 527-536.	2.3	23
85	Should New â€œNo Ink On Tumorâ€•Lumpectomy Margin Guidelines be Applied to Ductal Carcinoma In Situ (DCIS)? A Retrospective Review Using Shaved Cavity Margins. Annals of Surgical Oncology, 2016, 23, 3453-3458.	0.7	19
86	Dense Breasts: What Do Our Patients Need to Be Told and Why?. Annals of Surgical Oncology, 2016, 23, 3119-3127.	0.7	3
87	Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3128-3132.	0.7	1
88	Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger. Annals of Surgical Oncology, 2016, 23, 3212-3220.	0.7	26
89	A two-stage approach to genetic risk assessment in primary care. Breast Cancer Research and Treatment, 2016, 155, 375-383.	1.1	13
90	Occult Histopathology and Its Predictors in Contralateral and Bilateral Prophylactic Mastectomies. Annals of Surgical Oncology, 2016, 23, 767-775.	0.7	7

#	Article	IF	Citations
91	Implications of New Lumpectomy Margin Guidelines for Breast-Conserving Surgery: Changes in Reexcision Rates and Predicted Rates of Residual Tumor. Annals of Surgical Oncology, 2016, 23, 729-734.	0.7	42
92	Application of the 2015 American Cancer Society screening mammography guidelines: Risk assessment for women ages 40-44.. Journal of Clinical Oncology, 2016, 34, 1557-1557.	0.8	2
93	DCIS does not need treatmentâ€¦ really?. Breast Cancer Research and Treatment, 2015, 154, 1-4.	1.1	5
94	Management of Older Women with Early-Stage Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 48-55.	1.8	15
95	Lumpectomy specimen margins are not reliableÂin predicting residual disease in breast conserving surgery. American Journal of Surgery, 2015, 210, 93-98.	0.9	16
96	Can older women with early breast cancer avoid radiation?. Lancet Oncology, The, 2015, 16, 235-237.	5.1	19
97	Doing â€œnothingâ€•for DCIS: a case report. Breast Cancer Research and Treatment, 2015, 154, 435-437.	1.1	0
98	Genetics, Genomics, and Pharmacogenomics. Annals of Surgical Oncology, 2015, 22, 3414-3417.	0.7	0
99	Development, implementation, and initial evaluation of a foundational open interoperability standard for oncology treatment planning and summarization. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 577-586.	2.2	19
100	False-negative rate of combined mammography and ultrasound for women with palpable breast masses. Breast Cancer Research and Treatment, 2015, 153, 699-702.	1.1	23
101	Prediction of primary breast cancer size and T-stage using micro-computed tomography in lumpectomy specimens. Journal of Pathology Informatics, 2015, 6, 60.	0.8	14
102	Reply to A.S. Sie et al, K. Hemminki et al, and J. Larsen Haidle. Journal of Clinical Oncology, 2014, 32, 3346-3347.	0.8	0
103	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast. Archives of Pathology and Laboratory Medicine, 2014, 138, 595-601.	1.2	94
104	Clinical Decision Support for Personalized Medicine. , 2014, , 383-413.		1
105	Implementation of an electronic genomic and family health history tool in primary prenatal care. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 34-44.	0.7	17
106	Quality of Cancer Family History and Referral for Genetic Counseling and Testing Among Oncology Practices: A Pilot Test of Quality Measures As Part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. Journal of Clinical Oncology, 2014, 32, 824-829.	0.8	146
107	American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers. Journal of Clinical Oncology, 2014, 32, 833-840.	0.8	210
108	Surgical excision of radial scars diagnosed by core biopsy may help predict future risk of breast cancer. Breast Cancer Research and Treatment, 2014, 145, 331-338.	1.1	33

#	Article	IF	Citations
109	Evaluation of a Novel Electronic Genetic Screening and Clinical Decision Support Tool in Prenatal Clinical Settings. Maternal and Child Health Journal, 2014, 18, 1233-1245.	0.7	21
110	Implications of following the guidelines for genetic testing and MRI use for breast cancer.. Journal of Clinical Oncology, 2014, 32, 1549-1549.	0.8	0
111	The clinical oncology treatment plan and summary implementation guide: An interoperable HL7 document standard to improve the quality of cancer care.. Journal of Clinical Oncology, 2014, 32, 6603-6603.	0.8	0
112	Providing access to risk prediction tools via the HL7 XML-formatted risk web service. Breast Cancer Research and Treatment, 2013, 140, 187-193.	1.1	13
113	Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. Journal of Clinical Oncology, 2013, 31, 2382-2387.	0.8	998
114	Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs. Annals of Surgical Oncology, 2013, 20, 836-841.	0.7	25
115	Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Research and Treatment, 2013, 139, 571-579.	1.1	24
116	Reply to P.G. Tsoutsou et al, O. Kaidar-Person et al, and A. Courdi et al. Journal of Clinical Oncology, 2013, 31, 4571-4573.	0.8	2
117	Which Risk Model to Use? Clinical Implications of the ACS MRI Screening Guidelines. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 146-149.	1.1	59
118	Personalizing prenatal care using family health history: identifying a panel of conditions for a novel electronic genetic screening tool. Personalized Medicine, 2013, 10, 307-318.	0.8	4
119	The High-Tech High Risk Clinic. , 2013, , 161-167.		0
120	An interoperable HL7 document standard to improve the quality of cancer care across multiple locations.. Journal of Clinical Oncology, 2013, 31, 12-12.	0.8	1
121	Breast cancer risk assessment: How risk models can â€œoverdiagnoseâ€•risk.. Journal of Clinical Oncology, 2013, 31, 184-184.	0.8	0
122	Aromatase inhibition to decrease background parenchymal enhancement. Menopause, 2012, 19, 385-386.	0.8	0
123	Sentinel lymph node biopsy at the time of mastectomy does not increase the risk of lymphedema: implications for prophylactic surgery. Breast Cancer Research and Treatment, 2012, 135, 781-789.	1.1	22
124	The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Research and Treatment, 2012, 136, 627-633.	1.1	115
125	Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer. Annals of Surgical Oncology, 2012, 19, 3275-3281.	0.7	54
126	Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping. Breast Journal, 2012, 18, 303-311.	0.4	10

#	Article	IF	Citations
127	Determinants of outcome in elderly patients with positive sentinel lymph nodes. Breast Diseases, 2012, 23, 67-68.	0.0	0
128	Bias in the Reporting of Family History: Implications for Clinical Care. Journal of Genetic Counseling, 2012, 21, 547-556.	0.9	42
129	Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Breast Cancer Research and Treatment, 2012, 133, 735-740.	1.1	79
130	Managing Patients at High Risk for Hereditary Breast Cancer: A Guide for the Practicing Physician. Annals of Surgical Oncology, 2012, 19, 1721-1722.	0.7	1
131	Hereditary Breast and Ovarian Cancer and Other Hereditary Syndromes: Using Technology to Identify Carriers. Annals of Surgical Oncology, 2012, 19, 1732-1737.	0.7	96
132	Quality of cancer family history and referral for genetic counseling and testing among oncology practices: A pilot test of quality measures as part of the ASCO Quality Oncology Practice Initiative (QOPI).. Journal of Clinical Oncology, 2012, 30, CRA1505-CRA1505.	0.8	4
133	A program to increase use of chemoprevention for women with high-risk breast lesions.. Journal of Clinical Oncology, 2012, 30, 46-46.	0.8	1
134	The feasibility of using natural language processing to extract clinical information from breast pathology reports. Journal of Pathology Informatics, 2012, 3, 23.	0.8	86
135	Quality of cancer family history and referral for genetic counseling and testing among oncology practices: A pilot test of quality measures as part of the ASCO Quality Oncology Practice Initiative (QOPI).. Journal of Clinical Oncology, 2012, 30, CRA1505-CRA1505.	0.8	1
136	The complexity of breast cancer risk needs to be embraced, not oversimplified. Menopause, 2011, 18, 599-600.	0.8	0
137	The Safety of Multiple Re-excisions after Lumpectomy for Breast Cancer. Annals of Surgical Oncology, 2011, 18, 3797-3801.	0.7	48
138	Lumpectomy Cavity Shaved Margins Do Not Impact Re-excision Rates in Breast Cancer Patients. Annals of Surgical Oncology, 2011, 18, 3036-3040.	0.7	42
139	Oncology Lifeline - A Timeline Tool for the Interdisciplinary Management of Breast Cancer Patients in a Surgical Clinic. , 2010, , .		1
140	The Potential of the Electronic Health Record in the Breast Center. , 2010, , 953-960.		0
141	Clinical outcome of breast cancer occurring after treatment for Hodgkin's lymphoma: case-control analysis. Radiation Oncology, 2009, 4, 19.	1.2	23
142	Identification and Management of Women at High Risk for Hereditary Breast/Ovarian Cancer Syndrome. Breast Journal, 2009, 15, 155-162.	0.4	55
143	Electronic Health Records and the Management of Women at High Risk of Hereditary Breast and Ovarian Cancer. Breast Journal, 2009, 15, S46-S55.	0.4	21
144	Breast Cancer After Treatment of Hodgkin's Lymphoma: Risk Factors That Really Matter. International Journal of Radiation Oncology Biology Physics, 2009, 73, 69-74.	0.4	37

#	Article	IF	Citations
145	Outcome of multiple-wire localization for larger breast cancers: do multiple wires translate into additional imaging, biopsies, and recurrences?. American Journal of Surgery, 2009, 198, 368-372.	0.9	7
146	Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging. American Journal of Surgery, 2009, 198, 538-543.	0.9	53
147	Challenges and Improvements in the Identification of Women at High Risk. Breast Diseases, 2009, 20, 248-250.	0.0	1
148	The American Cancer Society guidelines for breast screening with magnetic resonance imaging. Cancer, 2008, 113, 3116-3120.	2.0	23
149	Sentinel Node Biopsy is Important in Mastectomy for Ductal Carcinoma In Situ. Annals of Surgical Oncology, 2008, 15, 268-273.	0.7	47
150	Outcomes of Multiple Wire Localization for Larger Breast Cancers: When Can Mastectomy Be Avoided?. Journal of the American College of Surgeons, 2008, 207, 342-346.	0.2	30
151	Why Do We Believe that Breast Cancer in the Elderly is the Same as Breast Cancer in Young Women?. Drugs and Aging, 2008, 25, 47-48.	1.3	2
152	Do sentinel node micrometastases predict recurrence risk in ductal carcinoma in situ and ductal carcinoma in situ with microinvasion?. American Journal of Surgery, 2008, 196, 566-568.	0.9	35
153	NCCN Task Force Report: Breast Cancer in the Older Woman. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, S-1-S-25.	2.3	30
154	Mammographic Breast Density and Race. American Journal of Roentgenology, 2007, 188, 1147-1150.	1.0	141
155	The use of radiation in the elderly. Breast Cancer Online: BCO, 2007, 10, 1-3.	0.1	2
156	Consensus Conference on Breast Conservation. Seminars in Breast Disease, 2007, 10, 178-185.	0.0	2
157	Management and Outcome of Ipsilateral Recurrence Following Breast Conservation. Seminars in Breast Disease, 2007, 10, 169-177.	0.0	0
158	Elastic stay hooks and self-retaining retractor technique for mastectomy skin flaps. Surgery, 2007, 141, 272-274.	1.0	4
159	Detecting Occult Malignancy in Prophylactic Mastectomy: Preoperative MRI Versus Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2007, 14, 2477-2484.	0.7	49
160	Accuracy of Self-Reported Personal History of Cancer in an Outpatient Breast Center. Journal of Genetic Counseling, 2007, 16, 341-345.	0.9	20
161	Breast Cancer Diagnosis in Women â‰¤ 40 versus 50 to 60 Years: Increasing Size and Stage Disparity Compared With Older Women Over Time. Annals of Surgical Oncology, 2006, 13, 1072-1077.	0.7	78
162	Initial dosimetric experience using simple three-dimensional conformal external-beam accelerated partial-breast irradiation. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1092-1099.	0.4	91

#	Article	IF	Citations
163	Accelerated partial-breast irradiation using proton beams: Initial clinical experience. International Journal of Radiation Oncology Biology Physics, 2006, 66, 691-698.	0.4	136
164	Consensus Conference on Breast Conservation. Journal of the American College of Surgeons, 2006, 203, 198-207.	0.2	74
165	Long-term Risk of False-Positive Screening Results and Subsequent Biopsy as a Function of Mammography Use. Radiology, 2006, 240, 335-342.	3.6	33
166	Evaluation of Hereditary Risk in a Mammography Population. Clinical Breast Cancer, 2005, 6, 38-44.	1.1	23
167	Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population. Cancer, 2005, 104, 1849-1853.	2.0	18
168	Family History Information Exchange Services Using HL7 Clinical Genomics Standard Specifications. International Journal on Semantic Web and Information Systems, 2005, 1, 44-67.	2.2	9
169	Palpable right breast mass in a pregnant woman. Nature Clinical Practice Oncology, 2005, 2, 218-221.	4.3	3
170	Radiological Reasoning:Male Breast Mass with Calcifications. American Journal of Roentgenology, 2005, 185, S205-S210.	1.0	25
171	Breast cancer treatment in older women. Surgical Oncology Clinics of North America, 2005, 14, 85-102.	0.6	7
172	1â€“52 The Relationship Among Physicians' Specialty, Perceptions of the Risks and Benefits of Adjuvant Tamoxifen Therapy, and Its Recommendation in Older Patients With Breast Cancer. Breast Diseases, 2005, 16, 95-96.	0.0	0
173	A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. American Journal of Surgery, 2005, 190, 517-520.	0.9	87
174	Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. New England Journal of Medicine, 2004, 351, 971-977.	13.9	958
175	Mammographic screening: Patterns of use and estimated impact on breast carcinoma survival. Cancer, 2004, 101, 495-507.	2.0	96
176	The age at which women begin mammographic screening. Cancer, 2004, 101, 1850-1859.	2.0	19
177	Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. Women's Oncology Review, 2004, 4, 293-295.	0.0	17
178	A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena. Cancer, 2003, 97, 2951-2959.	2.0	38
179	Racial differences in mammographic breast density. Cancer, 2003, 98, 590-596.	2.0	44
180	The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer, 2003, 98, 2133-2143.	2.0	129

#	Article	IF	Citations
181	Gauging the impact of breast carcinoma screening in terms of tumor size and death rate. Cancer, 2003, 98, 2114-2124.	2.0	68
182	Prevalence of Family History of Breast and Ovarian Cancer in a Single Primary Care Practice Using a Self-Administered Questionnaire. Breast Journal, 2003, 9, 19-25.	0.4	47
183	Efficacy of Computerized Infrared Imaging Analysis to Evaluate Mammographically Suspicious Lesions. American Journal of Roentgenology, 2003, 180, 263-269.	1.0	78
184	Estimates of the Sizes at Which Breast Cancers Become Detectable on Mammographic and Clinical Grounds. Journal of Women's Imaging, 2003, 5, 3-10.	0.2	42
185	Hormone therapy revisited: data from the population, treatment for the patient. Menopause, 2003, 10, 269-270.	0.8	0
186	Pretest Prediction of BRCA1 or BRCA2 Mutation by Risk Counselors and the Computer Model BRCAPRO. Journal of the National Cancer Institute, 2002, 94, 844-851.	3.0	140
187	BRCAPRO Validation, Sensitivity of Genetic Testing of BRCA1/BRCA2, and Prevalence of Other Breast Cancer Susceptibility Genes. Journal of Clinical Oncology, 2002, 20, 2701-2712.	0.8	477
188	Predicting the survival of patients with breast carcinoma using tumor size. Cancer, 2002, 95, 713-723.	2.0	178
189	Special Considerations when Treating Breast Cancer in the Elderly. Breast Disease, 2001, 12, 83-93.	0.4	1
190	Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. Journal of Clinical Pathology, 2001, 54, 91-97.	2.1	38
191	The Effectiveness of the Gail Model in Estimating Risk for Development of Breast Cancer in Women Under 40 Years of Age. Breast Journal, 2001, 7, 34-39.	0.4	35
192	The Management of Women at High Risk of Experiencing Hereditary Breast and Ovarian Cancer. Disease Management and Health Outcomes, 2000, 7, 201-215.	0.3	3
193	MULTIDISCIPLINARY CARE FOR PATIENTS WITH BREAST CANCER. Surgical Clinics of North America, 2000, 80, 505-533.	0.5	20
194	Prophylactic mastectomy and inherited predisposition to breast carcinoma. Cancer, 1999, 86, 1682-1696.	2.0	64
195	Prophylactic Surgery and Inherited Cancer Predisposition. , 1999, , 103-133.		1
196	The Development of New, Primary, Noninvasive Carcinoma of the Breast 29 Years after Bilateral Radical Mastectomy. Breast Journal, 1998, 4, 51-54.	0.4	2
197	Ductal Carcinoma In Situ: The Impact of Screening on Clinical Presentation and Pathologic Features. Breast Journal, 1998, 4, 146-151.	0.4	13
198	Germline PTEN mutations in Cowden syndrome-like families.. Journal of Medical Genetics, 1998, 35, 881-885.	1.5	140

#	Article	IF	Citations
199	Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bN0M0). Cancer, 1997, 79, 761-771.	2.0	68
200	Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bN0M0). Cancer, 1997, 79, 761-771.	2.0	1
201	Use of Carcinoembryonic Antigen Radioimmunodetection and Computed Tomography for Predicting the Resectability of Recurrent Colorectal Cancer. Annals of Surgery, 1997, 226, 621-631.	2.1	45
202	CONTROVERSIES IN THE TREATMENT OF DUCTAL CARCINOMA IN SITU. Surgical Clinics of North America, 1996, 76, 243-265.	0.5	8
203	Guest editorial: How do we apply genetic testing for breast cancer susceptibility to clinical practice?. , 1996, 62, 155-157.		1
204	Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome. Cancer, 1996, 77, 490-498.	2.0	211
205	Ductal carcinoma in situ of the male breast. Cancer, 1994, 74, 1289-1293.	2.0	63
206	Repeat liver resections from colorectal metastasis. Cancer Treatment and Research, 1994, 69, 185-196.	0.2	13
207	Causes of death in patients undergoing liver surgery. Cancer Treatment and Research, 1994, 69, 241-257.	0.2	23
208	Management of Recurrent and Metastatic Colorectal Carcinoma. Surgical Clinics of North America, 1993, 73, 145-166.	0.5	23
209	The Role of Axillary Dissection in Early Stage Breast Cancer. Cancer Investigation, 1992, 10, 461-470.	0.6	9
210	Common Operative Problems in Hepatobiliary Surgery. Surgical Clinics of North America, 1991, 71, 1363-1389.	0.5	8
211	Hepatic Resection Using Ultrasonic Fragmentation. Surgical Technology International, 1991, I, 89-96.	0.1	0
212	Morbidity and mortality of hepatic resection for metastatic colorectal carcinoma. Diseases of the Colon and Rectum, 1990, 33, 408-413.	0.7	35
213	Surgery for Colorectal Cancer Metastatic to the Liver: Optimizing the Results of Treatment. Surgical Clinics of North America, 1989, 69, 339-359.	0.5	236
214	Resection of the liver for colorectal carcinoma metastases. Diseases of the Colon and Rectum, 1988, 31, 1-4.	0.7	323
215	Intra-abdominal extrahepatic disease in patients with colorectal hepatic metastases. Diseases of the Colon and Rectum, 1988, 31, 100-103.	0.7	30
216	Extrahepatic Tumor Deposits Misdiagnosed as Intrahepatic Metastases. Archives of Surgery, 1988, 123, 1013.	2.3	9

#	Article	IF	Citations
217	Perioperative Blood Transfusions are Associated with Decreased Time to Recurrence and Decreased Survival after Resection of Colorectal Liver Metastases. Annals of Surgery, 1988, 208, 679-687.	2.1	226
218	Family History Information Exchange Services Using HL7 Clinical Genomics Standard Specifications. Advances in Semantic Web and Information Systems Series, 0, , 254-278.	0.0	2
219	Cancer Genetics Moves out of Its Winter of Discontent. Annals of Surgical Oncology, 0, , .	0.7	0